Long-term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group
- Citation:
- Cancer vol 113 (1) 108-116
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10 CA037417, N01 CA035431, U10 CA035269, CA-37404, CA-35090, U10 CA060276, CA-35195, U10 CA037404, U10 CA063848, U10 CA035195, CA-35103, CA-25224, CA-60276, U10 CA035272, CA-35113, U10 CA035101, U10 CA035113, P30 CA015083, CA-63848, U10 CA035415, U10 CA063849, CA-35415, U10 CA035431, CA-37417, CA-35272, CA-35269, CA-35101, U10 CA025224, U10 CA035090, CA-15083, CA-63849, N01 CA015083, U10 CA035103
- Corr. Author:
- Authors:
- David J. Inwards Paul A. S. Fishkin David W. Hillman David W. Brown Stephen M. Ansell Paul J. Kurtin Rafael Fonseca Roscoe F. Morton Michael H. Veeder Thomas E. Witzig
- Networks:
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- NCCTG-N0189, NCCTG-95-80-53
- Phases:
- 2
- Keywords:
- mantle cell lymphoma, cladribine, response duration, rituximab